| Literature DB >> 26384019 |
Priya Antony1, Ranjit Vijayan1.
Abstract
Hyperglycemia in diabetic patients results in a diverse range of complications such as diabetic retinopathy, neuropathy, nephropathy and cardiovascular diseases. The role of aldose reductase (AR), the key enzyme in the polyol pathway, in these complications is well established. Due to notable side-effects of several drugs, phytochemicals as an alternative has gained considerable importance for the treatment of several ailments. In order to evaluate the inhibitory effects of dietary spices on AR, a collection of phytochemicals were identified from Zingiber officinale (ginger), Curcuma longa (turmeric) Allium sativum (garlic) and Trigonella foenum graecum (fenugreek). Molecular docking was performed for lead identification and molecular dynamics simulations were performed to study the dynamic behaviour of these protein-ligand interactions. Gingerenones A, B and C, lariciresinol, quercetin and calebin A from these spices exhibited high docking score, binding affinity and sustained protein-ligand interactions. Rescoring of protein ligand interactions at the end of MD simulations produced binding scores that were better than the initially docked conformations. Docking results, ligand interactions and ADMET properties of these molecules were significantly better than commercially available AR inhibitors like epalrestat, sorbinil and ranirestat. Thus, these natural molecules could be potent AR inhibitors.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26384019 PMCID: PMC4575143 DOI: 10.1371/journal.pone.0138186
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Polyol pathway.
GlideScore and interacting residues from XP docking of various phytocompounds and drugs on AR targets.
| Target | Ligand | XP GlideScore (kcal/mol) | Hydrogen bonding residues | Residues forming π–π interactions |
|---|---|---|---|---|
| 4GCA | Gingerenone A | -13.02 | Thr113, Gln183 | Trp20, His110, Trp111, Tyr209 |
| 4GCA | Gingerenone B | -11.87 | Thr113 | Trp20, His110, Trp111, Tyr209 |
| 4GCA | Quercetin | -11.87 | Leu300, His110 | Trp20, His110, Trp111 |
| 4GCA | Lariciresinol | -11.77 | Gln183 | Trp20, His110, Trp111, Tyr209 |
| 4GCA | Calebin A | -11.76 | Thr113, Gln183 | Trp20, His110, Trp111, Tyr209 |
| 4GCA | Gingerenone C | -11.41 | Thr113, Gln183 | Trp20, His110, Trp111, Tyr209 |
| 4GCA | Ranirestat | -9.7 | Trp111, Tyr48 | Nil |
| 4GCA | Epalrestat | -9.5 | Trp20 | Trp111 |
| 4GCA | Sorbinil | -7.4 | Tyr48, His110 | Nil |
| 4LAU | Gingerenone B | -11.92 | Trp111, Gln183 | Trp20, His110, Trp111, Tyr209 |
| 4LAU | Gingerenone A | -11.66 | Thr113, Gln183 | His110, Trp111, Tyr209 |
| 4LAU | Quercetin | -11.55 | Thr113 | Trp79,Trp111 |
| 4LAU | Calebin A | -11.13 | Thr113, Asn160, Ala299 | Trp20, His110, Trp111 |
| 4LAU | Lariciresinol | -11.05 | Gln183 | Trp20, His110, Trp111, Tyr209 |
| 4LAU | Gingerenone C | -10.68 | Tyr48, His110, Thr113 | Trp111 |
| 4LAU | Epalrestat | -9.7 | Trp20 | Trp111 |
| 4LAU | Ranirestat | -9.2 | Tyr48, His110 | Trp111 |
| 4LAU | Sorbinil | -7.7 | Trp20, Trp111 | Phe122 |
| 1US0 | Gingerenone B | -11.63 | Tyr48, His110 | Trp111 |
| 1US0 | Gingerenone A | -11.77 | Thr113, Gln183 | His110, Trp111, Tyr209 |
| 1US0 | Quercetin | -11.53 | Thr113 | Trp79, Trp111, Phe122 |
| 1US0 | Gingerenone C | -11.50 | Thr113, Gln183 | His110, Trp111, Tyr209 |
| 1US0 | Lariciresinol | -11.48 | No H bonds | His110, Trp111, Tyr209 |
| 1US0 | Calebin A | -11.48 | Thr113, Gln183 | Trp20, His110, Trp111, Tyr209 |
| 1US0 | Ranirestat | -9.7 | Trp111 | Trp111 |
| 1US0 | Epalrestat | -9.4 | Trp20 | Trp111 |
| 1US0 | Sorbinil | -8.7 | Trp111 | Trp111 |
Binding energy calculated using MM-GBSA approach.
ΔGBinding energy is the sum of the other columns.
| Target | Ligand | ΔGBinding energy (kcal/mol) | ΔGCoulomb energy (kcal/mol) | ΔGCovalent binding energy (kcal/mol) | ΔGHydrogen-bonding energy (kcal/mol) | ΔGLipophilic energy (kcal/mol) | ΔG Van der Waals energy (kcal/mol) | ΔGPi-pi stacking energy (kcal/mol) | ΔG Generalized Born electrostatic solvation energy (kcal/mol) |
|---|---|---|---|---|---|---|---|---|---|
| 4GCA | Gingerenone A | -95.01 | -13.90 | 4.49 | -0.70 | -49.57 | -49.91 | -5.92 | 20.50 |
| 4GCA | Gingerenone B | -73.16 | -26.27 | 18.68 | 0.68 | -47.80 | -45.86 | -3.63 | 32.42 |
| 4GCA | Quercetin | -59.00 | -19.89 | 14.32 | -0.79 | -28.79 | -39.45 | -6.57 | 22.19 |
| 4GCA | Lariciresinol | -79.12 | -12.00 | 7.78 | -0.31 | -50.44 | -37.29 | -6.02 | 19.16 |
| 4GCA | Calebin A | -91.61 | -10.12 | 8.41 | -0.55 | -45.03 | -53.45 | -6.97 | 16.11 |
| 4GCA | Gingerenone C | -100.93 | -20.06 | 7.35 | -0.64 | -51.30 | -50.66 | -5.88 | 20.28 |
| 4GCA | Ranirestat | -70.06 | -3.65 | 6.02 | -0.62 | -37.26 | -36.96 | -1.81 | 4.25 |
| 4GCA | Epalrestat | -62.57 | -2.51 | 13.01 | -1.09 | -42.04 | -49.66 | -2.77 | 22.50 |
| 4GCA | Sorbinil | -48.33 | -8.63 | 1.01 | -0.63 | -17.72 | -25.09 | -0.84 | 3.57 |
| 4LAU | Gingerenone B | -76.74 | -11.36 | 14.15 | -0.72 | -56.91 | -32.50 | -4.26 | 14.86 |
| 4LAU | Gingerenone A | -88.19 | -13.59 | 10.46 | -0.67 | -55.89 | -41.99 | -7.61 | 21.10 |
| 4LAU | Quercetin | -60.52 | -12.89 | 3.06 | -0.48 | -29.11 | -35.62 | -11.67 | 26.20 |
| 4LAU | Calebin A | -85.78 | -9.36 | 9.19 | -0.86 | -53.43 | -41.0 | -4.17 | 13.88 |
| 4LAU | Lariciresinol | -85.51 | -4.83 | 6.88 | -0.27 | -48.82 | -49.45 | -7.05 | 18.03 |
| 4LAU | Gingerenone C | -76.61 | -10.35 | 0.26 | -0.54 | -39.32 | -41.87 | -4.51 | 19.73 |
| 4LAU | Epalrestat | -68.57 | 5.29 | 5.77 | -1.00 | -41.68 | -46.05 | -3.39 | 12.51 |
| 4LAU | Ranirestat | -88.03 | -9.22 | 5.10 | -0.60 | -37.80 | -42.86 | -5.56 | 2.91 |
| 4LAU | Sorbinil | -37.67 | -1.63 | 0.72 | -0.41 | -20.04 | -23.50 | -0.06 | 7.25 |
| 1US0 | Gingerenone B | -88.78 | -34.85 | 21.04 | -0.93 | -59.319 | -38.72 | -5.23 | 29.22 |
| 1US0 | Gingerenone A | -89.44 | -13.22 | 5.99 | -0.55 | -53.47 | -46.55 | -6.03 | 24.40 |
| 1US0 | Quercetin | -65.79 | -15.94 | 3.650 | -0.506 | -28.84 | -39.55 | -11.81 | 27.22 |
| 1US0 | Gingerenone C | -85.12 | -15.03 | 2.246 | -0.735 | -45.05 | -42.87 | -4.86 | 21.18 |
| 1US0 | Lariciresinol | -91.00 | -11.55 | 11.51 | -0.54 | -51.45 | -49.87 | -3.36 | 14.27 |
| 1US0 | Calebin A | -86.12 | -20.44 | 4.6 | -0.78 | -38.01 | -47.97 | -4.75 | 21.01 |
| 1US0 | Ranirestat | -74.73 | 4.32 | 5.03 | -0.33 | -39.42 | -46.57 | -4.85 | 7.09 |
| 1US0 | Epalrestat | -68.38 | -7.14 | 4.17 | -1.02 | -41.00 | -45.48 | -3.12 | 25.23 |
| 1US0 | Sorbinil | -47.16 | -2.18 | 3.09 | -0.18 | -25.14 | -28.93 | -5.39 | 11.58 |
Fig 2Chemical structure of lead molecules.
Fig 3Molecular interactions of lead compounds with AR (PDB ID: 4GCA).
(A) Structure of AR with the binding site region enclosed in a red box. (B) AR-gingerenone A complex (C) AR-gingerenone B complex (D) AR-gingerenone C complex (E) AR-calebin A complex (F) AR-lariciresinol complex (G) AR-quercetin complex. Protein is shown in grey cartoon representation, amino acid side chains are shown in stick representation and the docked ligand is in orange. Hydrogen bonds are shown as black dotted lines and π–π interactions are shown as blue lines.
Fig 4Ligand interaction diagram of lead compounds with AR (PDB ID: 4GCA).
(A) AR-gingerenone A complex (B) AR-gingerenone B complex (C) AR-gingerenone C complex (D) AR-calebin A complex (E) AR-lariciresinol complex (F) AR-quercetin complex. Colored circles indicate amino acids that interact with the bound ligand. Negatively charged amino acids are represented with red circles, positively charged amino acids are represented with dark blue circles, polar amino acids are represented with light blue circles and hydrophobic amino acids are represented with green circles. Hydrogen bonds are represented with purple arrows–dashed arrows for hydrogen bonds involving amino acid side chain and regular arrows for hydrogen bonds involving amino acid backbone. π–π interactions are shown with green lines.
Pharmacokinetic parameters of natural compounds and drugs.
| Name | Molecular weight | Oral absorption | CNS activity | BBB partition coefficient | Aqueous solubility | LogP | SASA |
|---|---|---|---|---|---|---|---|
| Range | <500 | >80%high <25%low | -2 inactive2 active | (-3.0 to 1.2) | (-6.5 to 0.5) | <5 | 300–1000 |
| Gingerenone A | 356.4 | 100 | -2 | -1.372 | -5.117 | 3.757 | 659.968 |
| Gingerenone B | 386.4 | 100 | -2 | -1.437 | -5.722 | 4.326 | 748.61 |
| Quercetin | 302.2 | 52.68 | -2 | -2.34 | -4.043 | 0.383 | 514.629 |
| Calebin A | 360.4 | 75.156 | -2 | -2.494 | -4.928 | 2.571 | 685.211 |
| Lariciresinol | 286.2 | 88.808 | -2 | -1.297 | -4.655 | 2.545 | 621.894 |
| Gingerenone C | 326.3 | 100 | -2 | -1.482 | -5.185 | 3.926 | 671.736 |
| Epalrestat | 319.3 | 84.701 | -1 | -0.945 | -4.448 | 3.62 | 567.965 |
| Sorbinil | 236.2 | 83.38 | 0 | -0.294 | -2.331 | 1.132 | 390.557 |
| Ranirestat | 420.1 | 88.24 | -1 | -0.743 | -4.301 | 2.945 | 555.515 |
Fig 5Residues of AR (PDB ID: 4GCA) that interact with the bound ligand and the number of interactions these residues make during the course of a 100 ns MD simulation.
(A) AR-gingerenone A complex (B) AR-gingerenone B complex. The x-axis represents the MD simulation time at which the interaction was evaluated and the y-axis shows all the residues that interacted with ligand at some point during the simulation. The intensity of brown bar at any time point indicates how many contacts (hydrophobic, hydrogen bonds, etc.) a residue makes with the ligand at that time.